Kelsey E Melah1, Sharon Yuan-Fu Lu2, Siobhan M Hoscheidt1, Andrew L Alexander2, Nagesh Adluru2, Daniel J Destiche2, Cynthia M Carlsson1, Henrik Zetterberg3,4, Kaj Blennow3, Ozioma C Okonkwo1,5, Carey E Gleason1,6, N Maritza Dowling1,7, Lisa C Bratzke8, Howard A Rowley9, Mark A Sager5, Sanjay Asthana1,6, Sterling C Johnson1,5,6, Barbara B Bendlin1,5. 1. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 2. Waisman Laboratory for Brain Imaging and Behavior, Madison, WI, USA. 3. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 4. UCL Institute of Neurology, Queen Square, London, UK. 5. Wisconsin Alzheimer's Institute, School of Medicine and Public Health, Madison, WI, USA. 6. Geriatric Research Education and Clinical Center, Wm. S. Middleton Memorial Veterans Hospital, Madison, WI, USA. 7. Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 8. School of Nursing, Wisconsin School of Medicine and Public Health, Madison, WI, USA. 9. Department of Neuroradiology, School of Medicine and Public Health, Madison, WI, USA.
Abstract
BACKGROUND: The immune response in Alzheimer's disease (AD) involves activation of microglia which may remove amyloid-β (Aβ). However, overproduction of inflammatory compounds may exacerbate neural damage in AD. AD pathology accumulates years before diagnosis, yet the extent to which neuroinflammation is involved in the earliest disease stages is unknown. OBJECTIVE: To determine whether neuroinflammation exacerbates neural damage in preclinical AD. METHODS: We utilized cerebrospinal fluid (CSF) and magnetic resonance imaging collected in 192 asymptomatic late-middle-aged adults (mean age = 60.98 years). Neuroinflammatory markers chitinase-3-like protein 1 (YKL-40) and monocyte chemoattractant protein-1 (MCP-1) in CSF were utilized as markers of neuroinflammation. Neural cell damage was assessed using CSF neurofilament light chain protein (NFL), CSF total tau (T-Tau), and neural microstructure assessed with diffusion tensor imaging (DTI). With regard to AD pathology, CSF Aβ42 and tau phosphorylated at threonine 181 (P-Tau181) were used as markers of amyloid and tau pathology, respectively. We hypothesized that higher YKL-40 and MCP-1 in the presence of AD pathology would be associated with higher NFL, T-Tau, and altered microstructure on DTI. RESULTS: Neuroinflammation was associated with markers of neural damage. Higher CSF YKL-40 was associated with both higher CSF NFL and T-Tau. Inflammation interacted with AD pathology, such that greater MCP-1 and lower Aβ42 was associated with altered microstructure in bilateral frontal and right temporal lobe and that greater MCP-1 and greater P-Tau181 was associated with altered microstructure in precuneus. CONCLUSION: Inflammation may play a role in neural damage in preclinical AD.
BACKGROUND: The immune response in Alzheimer's disease (AD) involves activation of microglia which may remove amyloid-β (Aβ). However, overproduction of inflammatory compounds may exacerbate neural damage in AD. AD pathology accumulates years before diagnosis, yet the extent to which neuroinflammation is involved in the earliest disease stages is unknown. OBJECTIVE: To determine whether neuroinflammation exacerbates neural damage in preclinical AD. METHODS: We utilized cerebrospinal fluid (CSF) and magnetic resonance imaging collected in 192 asymptomatic late-middle-aged adults (mean age = 60.98 years). Neuroinflammatory markers chitinase-3-like protein 1 (YKL-40) and monocyte chemoattractant protein-1 (MCP-1) in CSF were utilized as markers of neuroinflammation. Neural cell damage was assessed using CSF neurofilament light chain protein (NFL), CSF total tau (T-Tau), and neural microstructure assessed with diffusion tensor imaging (DTI). With regard to AD pathology, CSF Aβ42 and tau phosphorylated at threonine 181 (P-Tau181) were used as markers of amyloid and tau pathology, respectively. We hypothesized that higher YKL-40 and MCP-1 in the presence of AD pathology would be associated with higher NFL, T-Tau, and altered microstructure on DTI. RESULTS: Neuroinflammation was associated with markers of neural damage. Higher CSF YKL-40 was associated with both higher CSF NFL and T-Tau. Inflammation interacted with AD pathology, such that greater MCP-1 and lower Aβ42 was associated with altered microstructure in bilateral frontal and right temporal lobe and that greater MCP-1 and greater P-Tau181 was associated with altered microstructure in precuneus. CONCLUSION:Inflammation may play a role in neural damage in preclinical AD.
Authors: C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen Journal: Neurology Date: 1999-04-22 Impact factor: 9.910
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Christoffer Rosén; Carl-Henrik Andersson; Ulf Andreasson; José L Molinuevo; Maria Bjerke; Lorena Rami; Albert Lladó; Kaj Blennow; Henrik Zetterberg Journal: Dement Geriatr Cogn Dis Extra Date: 2014-07-31
Authors: Nagesh Adluru; Daniel J Destiche; Sharon Yuan-Fu Lu; Samuel T Doran; Alex C Birdsill; Kelsey E Melah; Ozioma C Okonkwo; Andrew L Alexander; N Maritza Dowling; Sterling C Johnson; Mark A Sager; Barbara B Bendlin Journal: Neuroimage Clin Date: 2014-04-21 Impact factor: 4.881
Authors: Annie M Racine; Alexandra Touroutoglou; Tatiana Abrantes; Bonnie Wong; Tamara G Fong; Michele Cavallari; Thomas G Travison; Yun Gou; Edward R Marcantonio; David C Alsop; Richard N Jones; Sharon K Inouye; Bradford C Dickerson Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Brianne M Bettcher; Sterling C Johnson; Ryan Fitch; Kaitlin B Casaletto; Kate S Heffernan; Sanjay Asthana; Henrik Zetterberg; Kaj Blennow; Cynthia M Carlsson; John Neuhaus; Barbara B Bendlin; Joel H Kramer Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Ione O C Woollacott; Jennifer M Nicholas; Carolin Heller; Martha S Foiani; Katrina M Moore; Lucy L Russell; Ross W Paterson; Ashvini Keshavan; Jonathan M Schott; Jason D Warren; Amanda Heslegrave; Henrik Zetterberg; Jonathan D Rohrer Journal: Dement Geriatr Cogn Disord Date: 2020-04-28 Impact factor: 2.959
Authors: Annie M Racine; Andrew P Merluzzi; Nagesh Adluru; Derek Norton; Rebecca L Koscik; Lindsay R Clark; Sara E Berman; Christopher R Nicholas; Sanjay Asthana; Andrew L Alexander; Kaj Blennow; Henrik Zetterberg; Won Hwa Kim; Vikas Singh; Cynthia M Carlsson; Barbara B Bendlin; Sterling C Johnson Journal: Brain Imaging Behav Date: 2019-02 Impact factor: 3.978
Authors: Elizabeth E Moore; Timothy J Hohman; Faizan S Badami; Kimberly R Pechman; Katie E Osborn; Lealani Mae Y Acosta; Susan P Bell; Michelle A Babicz; Katherine A Gifford; Adam W Anderson; Lee E Goldstein; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: Neurobiol Aging Date: 2018-06-28 Impact factor: 4.673